Financial Performance - Net profit attributable to shareholders was ¥43,068,027.30, representing a significant increase of 91.22% year-on-year[8]. - Operating revenue for the period was ¥451,223,197.37, reflecting a growth of 33.64% compared to the same period last year[8]. - Basic earnings per share were ¥0.1059, up 91.16% year-on-year[8]. - The company reported a net profit of ¥74,400,650.33 for the year-to-date, which is a 71.48% increase compared to the same period last year[8]. - The company's operating income for the period reached ¥1,240,055,722.52, a 27.34% increase compared to ¥973,803,606.68 in the same period last year, primarily due to increased sales in the pharmaceutical sector[18]. - The net profit attributable to shareholders was ¥74,400,650.33, reflecting a significant growth of 71.48% from ¥43,388,361.54, driven by expanded market efforts and a rebound in industry prices[18]. - Operating profit for the current period was ¥55,607,003.36, compared to ¥29,864,045.93 in the previous period, reflecting an increase of approximately 86.3%[37]. - Net profit for the current period was ¥51,929,066.85, significantly higher than ¥28,756,802.46 from the previous period, marking an increase of around 80.5%[37]. Cash Flow - The net cash flow from operating activities for the year-to-date reached ¥180,581,384.00, a remarkable increase of 356.85%[8]. - The cash flow from operating activities generated a net amount of CNY 180,581,384.00, a substantial increase from CNY 39,527,128.64 in the previous period[50]. - The net cash flow from operating activities for the current period is ¥66,504,849.49, compared to a negative cash flow of ¥56,545,695.26 in the previous period, indicating a significant improvement[54]. - The total cash inflow from financing activities is ¥947,710,996.03, up from ¥684,301,409.74 in the previous period, reflecting a 38.5% increase[52]. - The cash outflow from financing activities increased to ¥954,870,263.42 from ¥516,480,085.35, resulting in a net cash flow from financing activities of -¥7,159,267.39, compared to ¥167,821,324.39 previously[52]. - The cash inflow from investment activities is ¥115,853,621.51, significantly higher than ¥67,886,838.10 in the previous period, marking an increase of approximately 70.7%[52]. - The cash outflow from investment activities decreased to ¥247,135,317.84 from ¥283,886,625.60, indicating a reduction of about 13%[52]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,240,100,585.34, an increase of 10.27% compared to the end of the previous year[8]. - Current assets rose to CNY 2,124,703,534.65, up from CNY 1,724,292,460.65, indicating an increase of about 23.2%[28]. - Total liabilities increased to CNY 2,075,180,162.98 from CNY 1,755,055,076.63, representing a growth of approximately 18.3%[30]. - Owner's equity totaled CNY 2,164,920,422.36, up from CNY 2,090,216,569.28, indicating a slight increase of about 3.6%[30]. - The company’s long-term borrowings increased by 52.40% to ¥222,500,000.00 from ¥146,000,000.00, primarily due to increased borrowing by its subsidiary[18]. - The company’s inventory rose by 25.86% to ¥980,538,087.70 from ¥779,049,310.17, mainly due to increased stock of raw materials[18]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,491[12]. - The largest shareholder, Zhuhai Jindadi Investment Co., Ltd., held 34.82% of the shares, amounting to 141,615,094 shares[12]. - The company did not conduct any repurchase transactions among the top 10 shareholders during the reporting period[13]. Other Income and Expenses - The company reported a significant increase in other income, which rose by 102.91% to ¥24,325,966.88, primarily due to increased government subsidies received[18]. - Research and development expenses for the current period were ¥20,022,946.57, compared to ¥18,879,285.15 in the previous period, showing an increase of about 6%[35]. - Sales expenses rose to ¥44,842,226.89 from ¥34,632,589.09, indicating an increase of approximately 29.6%[35]. - Management expenses increased to ¥65,782,799.14 from ¥53,092,384.93, reflecting a growth of about 24%[35]. - The company reported an investment income of ¥898,585.35 for the current period, with no prior period data available for comparison[37]. Market Expansion - The company established a joint venture in Germany with Phytobiotics Futterzusatzstoffe GmbH to produce and sell enzyme preparations, with registration procedures currently underway[18].

Financial Performance - Total operating revenue for the first half of 2018 reached ¥788,832,525.15, representing a 24.00% increase compared to ¥636,175,383.48 in the same period last year[17]. - Net profit attributable to shareholders was ¥31,332,623.03, a significant increase of 50.17% from ¥20,865,433.91 year-on-year[17]. - The net profit after deducting non-recurring gains and losses was ¥23,545,774.82, up 44.67% from ¥21,613,461.22 in the previous year[17]. - Basic earnings per share rose to ¥0.0770, reflecting a 50.10% increase compared to ¥0.0513 in the same period last year[17]. - The company achieved a consolidated revenue of CNY 788.83 million, representing a 24.00% increase compared to the same period last year[44]. - The net profit attributable to shareholders was CNY 31.33 million, reflecting a growth of 50.17% year-on-year[44]. - The total comprehensive income for the first half of 2018 was CNY 44,671,160.90, compared to CNY 26,839,039.65 in the previous year, marking a significant increase[191]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,191,203,210.83, marking a 9.00% increase from ¥3,845,271,645.91 at the end of the previous year[17]. - Total liabilities reached CNY 2,078,211,855.32, up from CNY 1,755,055,076.63, indicating an increase of 18.43%[182]. - Owner's equity totaled CNY 2,112,991,355.51, slightly up from CNY 2,090,216,569.28, showing a marginal increase of 1.09%[183]. - Cash and cash equivalents increased to CNY 308,174,175.95 from CNY 213,935,277.00, a growth of 44.14%[180]. - Accounts receivable rose to CNY 610,422,986.00, up from CNY 539,563,326.30, reflecting an increase of 13.14%[180]. Investment and Expansion - The company plans to issue A-share convertible bonds, pending approval from the China Securities Regulatory Commission, which introduces uncertainty regarding the approval[4]. - The company is actively investing in the biopharmaceutical, agricultural, and industrial biotechnology sectors, which are supported by national policies and have significant market demand, despite increasing competition[4]. - The company is investing in Hunan Grei Biotechnology Co., Ltd. and Hunan Kangjie Biotechnology Co., Ltd. to enhance its enzyme production capacity and product series[30]. - The company has initiated the construction of an Industry 4.0 smart system and is working on eliminating outdated production capacity[43]. - The company plans to allocate CNY 3,000 million for the construction of a veterinary drug workshop at Hunan Chengda Biotechnology Co., Ltd., and CNY 4,000 million for GMP renovation at Henan Lihua Pharmaceutical Co., Ltd.[73]. Research and Development - The company has 99 invention patents and 11 core technologies, indicating a strong focus on innovation and R&D capabilities[37]. - R&D investment increased to ¥41,284,592.86, up 8.36% year-on-year[51]. - The company completed 15 research projects, with significant progress in key projects such as high-temperature resistant phytase and glucose oxidase[46]. - Research and development expenses increased by 30% to 100 million RMB, reflecting the company's commitment to innovation[96]. Market Strategy and Sales - The company adopts a market-oriented "sales-driven production" model to optimize inventory and improve operational efficiency[27]. - The sales model for biopharmaceuticals includes direct sales domestically and a combination of direct and distributor sales internationally[28]. - The company has established a marketing network covering over 60 countries and regions, with more than 2,300 high-quality direct sales customers[39]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for this purpose[96]. Financial Management - Financial expenses rose by 40.94% to CNY 39.98 million due to increased borrowing needs and rising interest costs[50]. - Long-term borrowings increased by 50.34% compared to the beginning of the year, mainly due to increased loans by Hunan Kangjie[34]. - The company has a stable management team with an average industry experience of over 19 years, ensuring effective leadership and operational continuity[38]. Compliance and Governance - The company has committed to timely and sufficient disclosure of share reduction information, with a notice to be published three working days prior to any reduction[116]. - The company has a commitment to comply with the regulations of the China Securities Regulatory Commission and the Shenzhen Stock Exchange regarding share transfers[103]. - The company has maintained compliance with its commitments to minority shareholders[131]. Operational Efficiency - The company emphasizes quality control throughout the production process, adhering to GMP standards[27]. - The company is focusing on optimizing business structure and enhancing profitability through asset evaluations and strategic sales[79]. - The management emphasized a focus on sustainable practices and compliance with regulatory standards in all operations[96].

Financial Performance - Total revenue for Q1 2018 was CNY 335,864,495.95, representing a 9.51% increase compared to CNY 306,687,565.40 in the same period last year[7] - Net profit attributable to shareholders was CNY 11,537,529.35, up 4.58% from CNY 11,031,967.88 year-on-year[7] - Basic and diluted earnings per share increased to CNY 0.0284, reflecting a growth of 4.80% from CNY 0.0271[7] - The company's total profit for Q1 2018 was CNY 26,598,858.75, representing a 56.67% increase from CNY 16,982,136.73 in the previous year[44] - The net profit for Q1 2018 reached CNY 20,776,953.57, up 43.83% from CNY 14,466,212.61 in Q1 2017[44] - The gross profit margin improved to 51.8% in Q1 2018, compared to 46.5% in Q1 2017[46] Cash Flow - Net cash flow from operating activities was negative CNY 4,824,356.70, a decline of 79.76% compared to positive CNY 14,225,666.87 in the previous year[7] - The company reported a cash inflow from operating activities of CNY 380,309,920.47 in Q1 2018, compared to CNY 223,426,902.85 in the previous year[49] - The net cash flow from operating activities was -4,824,356.70 CNY, compared to -23,840,333.13 CNY in the previous period, indicating an improvement[50] - Total cash inflow from financing activities was 305,285,000.00 CNY, up from 213,025,936.34 CNY year-over-year[51] - The net cash flow from investing activities was -83,378,661.65 CNY, slightly better than -92,866,156.47 CNY in the previous period[51] - The company reported a net increase in cash and cash equivalents of 13,605,325.55 CNY, compared to 4,721,455.37 CNY in the previous period[51] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,050,592,097.70, a 5.34% increase from CNY 3,845,271,645.91 at the end of the previous year[7] - Current liabilities rose to CNY 1,432,200,402.76, compared to CNY 1,393,193,723.61, indicating an increase of about 2.8%[36] - Long-term borrowings increased significantly to CNY 246,000,000.00 from CNY 146,000,000.00, marking a year-over-year increase of 68.5%[36] - The balance of accounts payable increased by 30 million yuan, a growth of 131.29%, mainly due to an increase in bank acceptance bills issued by the subsidiary Lihua Pharmaceutical[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,666[12] - The largest shareholder, Zhuhai Jindadi Investment Co., Ltd., held 34.82% of the shares, totaling 141,615,094 shares[12] - Net assets attributable to shareholders reached CNY 1,950,186,198.67, showing a slight increase of 0.60% from CNY 1,938,648,669.32[7] Investments and Projects - The total amount of funds raised was 726.51 million yuan, with 36.47 million yuan invested in the current quarter[25] - The total investment commitment for the enzyme preparation project in Inner Mongolia is 9,500 million, with a completion progress of 99.80% as of June 30, 2018[26] - The marketing service network construction project has a total investment of 2,500 million, with a completion progress of 74.80% as of December 31, 2018[26] - The new steroid hormone GMP construction project has a total investment of 40,000 million, with a completion progress of 78.49% as of December 31, 2018[26] Operational Performance - Total operating costs for Q1 2018 were CNY 313,478,575.54, up from CNY 293,029,716.71 in the previous year, reflecting a year-over-year increase of 7%[42] - The company's operating revenue for Q1 2018 was CNY 85,475,243.31, an increase of 36.29% compared to CNY 62,762,396.66 in the same period last year[46] - The company's financial expenses increased to CNY 6,940,475.89 in Q1 2018, up from CNY 3,859,793.32 in Q1 2017[46] Risks and Challenges - The company faced risks related to business integration and increasing financial expenses due to external financing[10] - The marketing service network construction project has not been completed due to delays in overseas product registration processes[28]

Financial Performance - The company's operating revenue for 2017 was approximately ¥1.50 billion, a decrease of 0.87% compared to ¥1.51 billion in 2016[16]. - The net profit attributable to shareholders for 2017 was approximately ¥80.42 million, down 29.18% from ¥113.57 million in 2016[16]. - The net profit after deducting non-recurring gains and losses was approximately ¥59.65 million, a decrease of 37.27% compared to ¥95.10 million in 2016[16]. - The company's total revenue for Q4 reached 525,459,715.96 CNY, marking a significant increase compared to previous quarters[18]. - The net profit attributable to shareholders for Q4 was 37,035,984.17 CNY, showing strong growth from Q1's 11,031,967.88 CNY[18]. - The company achieved a consolidated revenue of CNY 1,499.26 million in 2017, a decrease of 0.87% compared to the previous year[51]. - The net profit attributable to shareholders was CNY 80.42 million, down 29.18% year-on-year[51]. Assets and Liabilities - The company's total assets increased by 19.80% to approximately ¥3.85 billion at the end of 2017, up from ¥3.21 billion at the end of 2016[16]. - The net assets attributable to shareholders increased by 2.06% to approximately ¥1.94 billion at the end of 2017, compared to ¥1.90 billion at the end of 2016[16]. - Fixed assets increased by 24.10% year-on-year, primarily due to acquisitions and new production equipment[42]. - Intangible assets grew by 56.15% year-on-year, mainly from the purchase of land use rights by subsidiaries[42]. - Accounts receivable rose by 39.12% year-on-year, attributed to increased sales in the second half of the year[42]. - Short-term borrowings increased by 87.59% year-on-year due to higher operational funding needs[42]. Research and Development - The company has 87 invention patents and 11 core technologies, demonstrating strong R&D capabilities in enzyme products and biopharmaceuticals[45]. - The company’s R&D team consists of nearly 100 personnel with advanced degrees, ensuring a high level of expertise in product development[44]. - The company’s R&D investment for 2017 was ¥93,931,075.15, representing 6.27% of total revenue, with a total of 344 R&D personnel, which is 14.33% of the workforce[75]. - The company made substantial advancements in research and development, including breakthroughs in high-temperature resistant phytase and other enzymes[55]. Market and Product Development - The company is engaged in the development and sales of biopharmaceuticals, biological enzyme preparations, and functional additives, focusing on modern biotechnology applications[25]. - Key products include immunological and respiratory system drugs, reproductive health system drugs, and various biological enzyme preparations[25][26]. - The company launched new product development initiatives, achieving significant progress with over ten products developed during the year[52]. - The company is focused on upgrading its production standards and quality requirements to transition from a large to a strong player in the enzyme preparation industry[31]. - The company is actively constructing production facilities for its subsidiaries, which will enhance its enzyme production capacity and product series upon completion[31]. Strategic Acquisitions and Investments - The company has actively expanded its business through acquisitions, including Hunan Hongying Biotechnology Co., Ltd. and Hunan Xinhong New Pharmaceutical Co., Ltd.[4]. - The company is acquiring a 51% stake in Changsha Shiwai Technology Co., which will strengthen its competitive position in the medicinal plant extraction sector[33]. - The company plans to temporarily use CNY 50,000 million of idle raised funds to supplement working capital, with a usage period not exceeding 12 months[94]. - The company has committed a total investment of CNY 72,413.56 million for various projects, with a cumulative investment of CNY 16,074.51 million, representing 22.15% of the total commitment[93]. Dividend and Profit Distribution - The board approved a profit distribution plan, proposing a cash dividend of ¥0.40 per 10 shares, with no bonus shares issued[4]. - The cash dividend policy for 2017 includes a distribution of RMB 0.4 per 10 shares, totaling RMB 16,270,214.64, which represents 100% of the profit distribution[116][118]. - In 2017, the cash dividend amount was 16,270,214.64, representing 20.23% of the net profit attributable to ordinary shareholders of 80,424,345.71[120]. Compliance and Governance - The company has established measures to prevent any conflicts of interest and ensure compliance with commitments regarding related party transactions[124]. - The company will adhere to the provisions of the Company Law and relevant regulations to protect shareholder rights[124]. - The company has maintained compliance with the regulations regarding the management and usage of raised funds[90]. - The company has a long-term commitment to avoid any illegal occupation of assets and ensure compliance with all agreements made[124]. Future Outlook - Future outlook indicates a projected revenue growth of 10% for 2018, driven by new product launches and market expansion strategies[127]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[131]. - The company aims to improve operational efficiency by 15% through the implementation of new technologies in production processes[136]. - The company has outlined a strategic acquisition plan to enhance its product portfolio, with a budget of RMB 500 million allocated for potential acquisitions[132].

Financial Performance - The company's operating revenue for 2017 was approximately ¥1.50 billion, a decrease of 0.87% compared to ¥1.51 billion in 2016[16]. - The net profit attributable to shareholders for 2017 was approximately ¥80.42 million, down 29.18% from ¥113.57 million in 2016[16]. - The net profit after deducting non-recurring gains and losses was approximately ¥59.65 million, a decrease of 37.27% compared to ¥95.10 million in 2016[16]. - The basic earnings per share for 2017 was ¥0.1977, a decline of 33.19% from ¥0.2959 in 2016[16]. - The weighted average return on net assets was 4.19% in 2017, down from 7.07% in 2016[16]. - The company achieved a consolidated revenue of 1,499.26 million RMB in 2017, a decrease of 0.87% compared to the previous year[51]. - The net profit attributable to shareholders was 80.42 million RMB, down 29.18% year-on-year[51]. - The company reported a net profit attributable to shareholders of RMB 80,424,345.71 for 2017, with a total distributable profit of RMB 463,617,595.90 at year-end[118]. Assets and Liabilities - The company's total assets increased by 19.80% to approximately ¥3.85 billion at the end of 2017, up from ¥3.21 billion at the end of 2016[16]. - The net assets attributable to shareholders increased by 2.06% to approximately ¥1.94 billion at the end of 2017, compared to ¥1.90 billion at the end of 2016[16]. - Fixed assets increased by 24.10% year-on-year, primarily due to acquisitions and new production equipment[42]. - Intangible assets grew by 56.15% year-on-year, mainly from the purchase of land use rights by subsidiaries[42]. - Accounts receivable rose by 39.12% year-on-year, attributed to increased sales in the second half of the year[42]. - Short-term borrowings increased by 87.59% year-on-year, indicating a rise in operational funding needs[42]. - The total amount of accounts receivable increased by 39.12% year-on-year, reaching 539.56 million RMB, attributed to increased sales from the subsidiary Xinhexin[81]. - Inventory increased by 28.11% year-on-year, totaling 779.05 million RMB, due to longer production cycles and increased raw materials and semi-finished goods[81]. Business Strategy and Expansion - The company has actively expanded its business through acquisitions, including Hunan Hongying Biotechnology Co., Ltd. and Hunan Xinhong New Pharmaceutical Co., Ltd.[4]. - The company plans to continue investing in the biopharmaceutical, agricultural, and industrial biotechnology sectors, which are supported by national policies and have significant market demand[4]. - The company expanded its production bases in Hunan, Henan, and Beijing, enhancing its cost advantage and regional layout[49]. - The company is acquiring a 51% stake in Changsha Shiwai Technology Co., which will strengthen its position in the medicinal plant extraction sector and improve profitability through synergies[33]. - The company is focusing on the industrialization of several key R&D projects, including corticosteroid intermediates and raw materials, to reduce costs and enhance product offerings[75]. - The company is investing in the construction of the Yidali Biopharmaceutical Industrial Park to expand production capacity and optimize production processes[107]. Research and Development - The company’s R&D team consists of nearly 100 personnel with advanced degrees, ensuring a robust innovation pipeline[44]. - The company’s R&D investment for 2017 was ¥93,931,075.15, representing 6.27% of total operating revenue[75]. - The number of R&D personnel increased to 344, which is 14.33% of the total workforce, up from 12.89% in 2016[76]. - The company made significant progress in R&D, including breakthroughs in high-temperature resistant phytase and other enzyme products[55]. - The company is leveraging advanced genetic engineering and fermentation technologies to innovate in the production of pharmaceutical intermediates, enhancing its competitive edge[32]. Market and Sales - The company's sales model primarily relies on direct sales, supported by a distribution network, to penetrate both domestic and international markets[30]. - The marketing network covers over 60 countries and regions, with more than 2,300 high-quality direct sales customers[49]. - The company launched over ten new products in 2017, contributing significantly to its operational performance[52]. - The overseas marketing center achieved rapid growth in performance, supported by the establishment of new marketing departments[53]. - The company is exploring potential acquisitions to strengthen its supply chain and distribution network, with a budget of 500 million RMB allocated for this purpose[128]. Profit Distribution and Dividends - The board approved a profit distribution plan, proposing a cash dividend of ¥0.40 per 10 shares, with no bonus shares issued[4]. - The cash dividend policy for 2017 includes a distribution of RMB 0.4 per 10 shares, totaling RMB 16,270,214.64, which represents 100% of the profit distribution[116][118]. - In 2017, the cash dividend amount was 16,270,214.64, representing 20.23% of the net profit attributable to ordinary shareholders of 80,424,345.71[120]. - In 2016, the cash dividend amount was 37,963,834.16, which accounted for 33.43% of the net profit attributable to ordinary shareholders of 113,566,059.43[120]. Compliance and Governance - The company has maintained a stable shareholding structure with no non-operating fund occupation by controlling shareholders[164]. - The company has no significant litigation or arbitration matters during the reporting period[168]. - The company has fulfilled its commitments to minority shareholders in a timely manner[161]. - The company will ensure compliance with shareholder rights as per the Company Law and relevant regulations during decision-making processes[124]. - The company has established measures to prevent any illegal occupation of assets or conflicts of interest in related transactions[124]. Corporate Social Responsibility - The company actively fulfills its corporate social responsibilities, ensuring shareholder value while also addressing the needs of employees and other stakeholders[196]. - The company emphasizes employee rights protection and provides various training programs to enhance employee skills and satisfaction[197]. - The company has established the "Yidoli Scholarship" in several colleges and has engaged in multiple poverty alleviation initiatives[197]. - The company adheres to environmental protection regulations and has implemented an EHS management system to ensure zero accidents in safety and environmental production[199].

2017 年第三季度报告 2017-111 2017 年 10 月 广东溢多利生物科技股份有限公司 2017 年第三季度报告全文 广东溢多利生物科技股份有限公司 1 广东溢多利生物科技股份有限公司 2017 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈少美、主管会计工作负责人李著及会计机构负责人(会计主管 人员)朴希春声明：保证季度报告中财务报表的真实、准确、完整。 2 广东溢多利生物科技股份有限公司 2017 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 3,568,555,647.43 | 3,209,816,242.37 | | 11.18% | | 归属于上市公司 ...

Financial Performance - Total revenue for the first half of 2017 was CNY 636,175,383.48, an increase of 2.30% compared to CNY 621,898,649.79 in the same period last year[22]. - Net profit attributable to shareholders decreased by 35.42% to CNY 20,865,433.91 from CNY 32,308,472.90 year-on-year[22]. - Net profit after deducting non-recurring gains and losses was CNY 21,613,461.22, down 21.03% from CNY 27,368,798.44 in the previous year[22]. - Basic earnings per share decreased by 42.68% to CNY 0.0513 from CNY 0.0895 in the previous year[22]. - The company achieved operating revenue of 636.18 million yuan, an increase of 2.30% compared to the same period last year[29]. - The net profit attributable to the parent company's shareholders was 20.87 million yuan, a decrease of 35.42% year-on-year[29]. - The company reported a net cash outflow from investment activities of -¥245,723,542.17, which is a 29.79% increase in outflow compared to -¥189,322,976.31 in the previous year[50]. - The company reported a decrease in cash and cash equivalents, with RMB 151,694,541.76 at the end of the period, down from RMB 229,314,436.76, a decline of approximately 33.8%[161]. Cash Flow and Investments - Operating cash flow improved significantly, with a net cash flow from operating activities of CNY 103,593,482.84, compared to a negative CNY 87,548,473.05 in the same period last year, representing a 218.33% increase[22]. - The cash flow from operating activities saw a significant increase of 218.33%, reaching ¥103,593,482.84, compared to a negative cash flow of -¥87,548,473.05 in the previous year[50]. - The company reported a significant increase of 132.03% in tax and additional fees, amounting to ¥5,811,935.63, compared to ¥2,504,851.62 in the previous year[51]. - The company reported a net cash flow from financing activities increased to 18,592,893.38 CNY, compared to 616,938,584.04 CNY in the previous period[182]. Assets and Liabilities - Total assets increased by 6.05% to CNY 3,404,092,800.86 from CNY 3,209,816,242.37 at the end of the previous year[22]. - The total liabilities of the company reached RMB 1,353,082,904.02, compared to RMB 1,155,187,294.66 at the beginning of the period, which is an increase of approximately 17.14%[164]. - The company's equity attributable to shareholders was RMB 1,896,058,982.29, slightly decreasing from RMB 1,899,598,870.34, indicating a marginal decline of about 0.19%[164]. - The company's current assets totaled RMB 1,422,952,904.37, up from RMB 1,360,104,056.27, indicating an increase of about 4.63%[162]. Market and Competition - The company faces risks from natural disasters and livestock epidemics that could impact demand for its products[5]. - Increased market competition in steroid hormone drugs and industrial enzyme products may adversely affect the company's performance if it fails to adapt[6]. - The company plans to continuously enrich its product variety and balance its product structure to effectively respond to the risks of disease in single aquaculture species, thereby improving its overall risk resistance capability[85]. - The company faces intensified market competition in steroid hormone drugs and certain industrial enzyme products, which may adversely affect its performance if it fails to adapt its R&D and marketing strategies[85]. Research and Development - The company has established a comprehensive and advanced R&D system with nearly 100 technical personnel holding doctoral or master's degrees[36]. - The company completed the filing for six invention patents and 16 technology project applications during the reporting period[44]. - New product development efforts led to the completion of 4 new products and 3 process optimization improvements during the reporting period[80]. - The company has filed for 3 invention patents during the reporting period, reflecting its commitment to innovation[83]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares[9]. - The company implemented its first employee stock ownership plan, involving 170 employees, with a total shareholding of 18 million shares, accounting for 4.43% of the total share capital[115]. - The company has made commitments to minority shareholders, which have been fulfilled in a timely manner[106]. - The company’s controlling shareholders must notify the company of their specific plans for share purchases within 2 working days upon triggering the stabilization plan[100]. Risk Management - The company has a risk of goodwill impairment that could negatively impact its current profit and loss if the operating conditions of its merged entities worsen[85]. - The company faces risks related to natural disasters and livestock epidemics, which could impact the demand for its feed enzyme products[84]. - The company has formed a certain amount of goodwill in its consolidated balance sheet after merging with Xinhe and Lihua Pharmaceutical, which requires annual impairment testing; deterioration in their operating conditions may lead to goodwill impairment risks[85].

广东溢多利生物科技股份有限公司 2017 年第一季度报告全文 广东溢多利生物科技股份有限公司 2017 年第一季度报告 2017-036 2017 年 04 月 1 广东溢多利生物科技股份有限公司 2017 年第一季度报告全文 第一节 重要提示 公司负责人陈少美、主管会计工作负责人李著及会计机构负责人(会计主管 人员)朴希春声明：保证季度报告中财务报表的真实、准确、完整。 2 广东溢多利生物科技股份有限公司 2017 年第一季度报告全文 第二节 公司基本情况 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目，以及把《公 开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应 说明原因 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | ...

Financial Performance - The company's operating revenue for 2016 was CNY 1,512,440,992.15, representing a 115.00% increase compared to CNY 703,472,717.98 in 2015[20]. - The net profit attributable to shareholders for 2016 was CNY 113,566,059.43, a 58.11% increase from CNY 71,829,414.10 in 2015[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 95,095,248.71, up 40.09% from CNY 67,882,204.07 in 2015[20]. - The total assets at the end of 2016 reached CNY 3,209,816,242.37, a 30.89% increase from CNY 2,452,262,377.63 at the end of 2015[20]. - The net assets attributable to shareholders at the end of 2016 were CNY 1,899,598,870.34, reflecting a 46.58% increase from CNY 1,295,918,686.18 at the end of 2015[20]. - The basic earnings per share for 2016 was CNY 0.2959, a 26.45% increase from CNY 0.2340 in 2015[20]. - The company achieved consolidated revenue of CNY 1,512.44 million, a 115.00% increase compared to the previous year[53]. - Net profit attributable to shareholders reached CNY 113.57 million, reflecting a growth of 58.11% year-on-year[53]. Cash Flow and Investments - The company faced a net cash flow from operating activities of CNY -44,127,713.72, a decline of 181.48% compared to CNY 54,158,885.73 in 2015[20]. - The net cash flow from operating activities was negative in the first two quarters, with -60,117,642.87 CNY in Q1 and -27,430,830.18 CNY in Q2, but turned positive in Q3 and Q4, reaching 18,844,600.11 CNY and 24,576,159.22 CNY respectively[22]. - The company reported a significant decrease in investment amounting to CNY 108,000,000, a decline of 86.96% compared to the previous year's investment of CNY 828,000,000[91]. - The company plans to non-publicly issue shares to raise funds for projects including 15,000 tons of food-grade enzyme production and 1,200 tons of steroid drugs and intermediates[49]. Business Expansion and Acquisitions - The company has expanded its business through acquisitions, including Hunan Hongying Biotechnology Co., Ltd. and Hunan Xinhongxin Biopharmaceutical Co., Ltd., enhancing its enzyme product applications[5]. - The company invested in Hunan Grey Biotechnology Co., Ltd. and Hunan Kangjie Biotechnology Co., Ltd. to enhance its enzyme production capacity and product series[36]. - The company acquired 100% of Zhuhai Ruikang Biotechnology Co., Ltd. and 70% of Hunan Longteng Biotechnology Co., Ltd., enhancing production capacity and optimizing production layout[108]. Research and Development - The company’s research and development efforts are focused on innovative biotechnological solutions to address ecological and health challenges globally[31]. - The company completed several R&D projects, including the industrialization of 6 new steroid intermediates, enhancing its product portfolio[76]. - The company plans to strengthen R&D investment and enhance core technological competitiveness to support the development of new products and extend the industrial chain[120]. - The company has 85 invention patents and 11 core technologies, indicating a strong focus on innovation[47]. Market and Product Development - The company is actively investing in the biopharmaceutical and agricultural industries, which are supported by national policies and have significant market demand, despite increasing competition[5]. - The company aims to enhance its product lines, including biological enzyme preparations and microbial preparations, while actively expanding application fields to strengthen its market position[113]. - The company plans to launch three new products in 2017, focusing on health supplements and biotechnology innovations[141]. Financial Management and Governance - The company has a stable management team with an average tenure of over 16 years, providing a solid foundation for sustainable growth[48]. - The company is focused on enhancing its governance structure and management systems to improve core competitiveness and achieve its strategic goals[115]. - The company has committed to fulfilling promises made by major shareholders and related parties during the reporting period[133]. Dividend Policy - The board approved a profit distribution plan, proposing a cash dividend of CNY 0.60 per 10 shares for all shareholders[7]. - The cash dividend accounted for 100% of the total profit distribution amount, reflecting the company's strategy to retain funds for business expansion and development[128]. - The company did not distribute profits for 2015 due to significant acquisitions, including 100% stakes in Henan Lihua Pharmaceutical Co., Ltd. and Zhuhai Ruikang Biological Co., Ltd.[126]. Compliance and Risk Management - There were no significant discrepancies between financial reports prepared under international accounting standards and those under Chinese accounting standards during the reporting period[23][24]. - The company has a structured approach to managing its financial guarantees, ensuring compliance and risk management[200]. - The company has no significant litigation or arbitration matters during the reporting period[183].

Financial Performance - Total assets increased by 27.66% to CNY 3,130,456,030.74 compared to the end of the previous year[8] - Net assets attributable to shareholders rose by 43.98% to CNY 1,865,891,490.81 year-over-year[8] - Total operating revenue for the period reached CNY 368,332,301.73, a 135.86% increase compared to the same period last year[8] - Net profit attributable to shareholders increased by 31.68% to CNY 33,991,694.80[8] - The net profit after deducting non-recurring gains and losses was CNY 32,389,351.96, up 27.70% year-over-year[8] - Basic earnings per share increased by 7.71% to CNY 0.2711[8] - The company's operating revenue for the year-to-date reached CNY 990,230,951.52, a significant increase of 138.17% compared to CNY 415,759,183.57 in the same period last year[19] - The company reported a significant increase in revenue for Q3 2016, with a year-over-year growth of 15%[29] - The company achieved a net profit of 30 million RMB in Q3 2016, up 15% compared to the same period last year[34] - The total operating revenue for the third quarter was CNY 368,332,301.73, a significant increase from CNY 156,163,720.96 in the same period last year, representing a growth of approximately 135.5%[83] Cash Flow and Financing - The company reported a significant negative cash flow from operating activities of CNY -68,703,872.94, a decrease of 538.67%[8] - The net cash flow from financing activities increased by 212.05% to CNY 562,969,982.43, primarily due to capital increases and increased borrowings[19] - Cash and cash equivalents rose to CNY 246,720,422.11, reflecting a 244.83% increase from CNY 71,548,620.42 in the previous year[19] - The cash flow from operating activities showed a net outflow of CNY -68,703,872.94, contrasting with a net inflow of CNY 15,661,967.10 in the previous year[99] - The net cash flow from operating activities was -119,509,510.88 CNY, compared to -6,374,540.27 CNY in the previous period, indicating a significant decline in operational cash generation[103] - Cash inflow from financing activities amounted to 736,000,000.27 CNY, a substantial increase from 186,496,917.27 CNY in the previous period[104] - The net cash flow from financing activities was 482,446,980.24 CNY, compared to 165,376,224.21 CNY in the previous period, indicating improved financing efficiency[104] Operational Costs and Expenses - Management expenses surged by 207.32% to CNY 143,222,765.90, mainly due to the consolidation of new subsidiaries[19] - The company reported a 185.26% increase in operating costs, totaling CNY 612,739,150.39, linked to the addition of new subsidiaries[19] - The total operating costs for the quarter amounted to CNY 321,289,769.77, compared to CNY 124,426,125.09 in the previous year, indicating a year-over-year increase of about 158.5%[83] - The company reported a significant increase in sales expenses, totaling CNY 41,043,733.11, compared to CNY 30,620,716.08 in the previous year, reflecting a rise of approximately 34%[84] - The management expenses for the third quarter of 2016 were CNY 50,177,227.96, which is a substantial increase from CNY 16,295,490.30 in the same period last year[84] Market and Product Development - The company expanded its business scope into pharmaceuticals and intermediates, enhancing its product offerings and market reach[11] - The company has initiated the safety evaluation and application for two new products and filed three invention patents during the reporting period[24] - The company achieved significant improvements in production efficiency and quality management, with the Inner Mongolia production base obtaining a food additive production license[24] - New product launches are expected to contribute an additional $5 million in revenue in the next quarter[30] - New product development includes a line of health supplements expected to launch in Q1 2017, projected to contribute an additional 50 million RMB in revenue[33] Shareholder and Equity Information - The total number of shareholders at the end of the reporting period was 8,446[13] - The company distributed a cash dividend of 1.00 yuan per 10 shares to all shareholders, with a capital reserve conversion of 20 shares for every 10 shares held, effective October 18, 2016[68] - The company has committed to not transferring or repurchasing shares for 36 months from the date of listing[37] - The maximum annual reduction in shareholding for major shareholders is set at 5% of the total share capital after the lock-up period[38] - The company’s major shareholder, Wang Shichen, is restricted from reducing holdings exceeding the total shares held before the initial public offering[41] Strategic Initiatives and Future Outlook - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of $50 million allocated for potential deals[30] - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of 2017[29] - Future guidance estimates a revenue growth of 15-20% for the next quarter, driven by increased sales and new product launches[34] - A new marketing strategy was introduced, aiming to increase brand awareness by 15% over the next year[44] - The company plans to enhance its online sales platform, aiming for a 15% increase in e-commerce sales by Q1 2017[31] Compliance and Regulatory Matters - The management emphasized the importance of compliance with regulatory requirements in all operational aspects[44] - The company committed to compensating 1 million RMB to Yidoli if any non-compliance with the commitment is proven[48] - The company has established a commitment to comply with relevant regulations regarding share transfers and reductions[41] - The company will disclose share reduction intentions three working days prior to any reduction[40] Investment and Fund Utilization - The total amount of raised funds is 72,413.56 million CNY, with 8,253.35 million CNY invested in the current quarter[64] - Cumulative investment of raised funds reached 37,724.87 million CNY, representing 52.1% of the total raised amount[64] - The project for producing 20,000 tons of enzyme preparations in Inner Mongolia has achieved an investment completion rate of 99.80%[64] - The company approved the temporary use of 150 million yuan of idle raised funds to supplement working capital, with a usage period not exceeding 12 months[66] - There were no significant issues reported regarding the use and disclosure of raised funds during the reporting period[67]